
Sep 12, 2026
ADC Therapeutics SA (NYSE:ADCT) Receives Average Recommendation of "Hold" from Brokerages
ADC Therapeutics SA (NYSE:ADCT) has received an average "Hold" rating from six brokerages, with an average 12-month price target of $5.00. The company recently reported an adjusted loss of $0.11 per share and $19.25 million in revenue, surpassing analyst estimates. Institutional investors and hedge funds currently own 41.1% of the stock.
Company relevance
100.00%
Company sentiment
Neutral
Overall sentiment
Neutral